All In Biotech

Drug Trial Radar · NCT04918771

Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old

Multicenter Double Blind Placebo-controlled Parallel-group Randomized Clinical Study of Efficacy and Safety of Raphamin in the Treatment of Acute Respiratory Viral Infection in Children Aged 12-18 Years Old

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 435 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

435

Actual

Start

Apr 29, 2021

Primary completion

Jul 21, 2023

Study completion Jul 21, 2023

Sponsor

Lead sponsor
Materia Medica HoldingIndustry
Sponsor type
Industry
First posted
Jun 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children aged 12-18 years old.

Conditions

  • Acute Respiratory Viral Infection

Interventions

  • RaphaminDrug

    Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved. On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.

  • PlaceboDrug

    Oral administration - not with food. Placebo using Raphamin scheme.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).Time frame: 14 days of observation

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Kazan State Medical University

    Kazan', Russia

  • Llc "Medlight"

    Kazan', Russia

  • Specialized Clinical Hospital for Infectious Diseases

    Krasnodar, Russia

  • Llc "Olla-Med"

    Moscow, Russia

  • Russian National Research Medical University named after N.I. Pirogov

    Moscow, Russia

  • Morozovskaya Children's City Clinical Hospital of the Moscow Department of Health

    Moscow, Russia

  • Federal Scientific and Clinical Center for Physical and Chemical Medicine of the Federal Medical and Biological Agency

    Moscow, Russia

  • Llc "Diagnostics and Vaccines"

    Moscow, Russia

  • Novosibirsk State Medical University

    Novosibirsk, Russia

  • City Children's Clinical Polyclinic # 5

    Perm, Russia

  • LLC "Professorial Clinic"

    Perm, Russia

  • Clinical and diagnostic center "Health" of the city of Rostov-on-Don

    Rostov-on-Don, Russia

  • Children's City Hospital #1 of Rostov-on-Don city

    Rostov-on-Don, Russia

  • Rostov State Medical University

    Rostov-on-Don, Russia

  • Ryazan State Medical University named after academician I.P. Pavlov

    Ryazan, Russia

  • Children's city polyclinic # 44

    Saint Petersburg, Russia

  • LLC "Energy of health"

    Saint Petersburg, Russia

  • Children's city polyclinic # 35

    Saint Petersburg, Russia

  • Research Institute of Influenza named after A.A. Smorodintsev

    Saint Petersburg, Russia

  • Samara Regional Children's Clinical Hospital named after N.N. Ivanova

    Samara, Russia

  • National Research Mordovian State University named after N.P. Ogarev

    Saransk, Russia

  • LLC "DNA Research Center"

    Saratov, Russia

  • Smolensk State Medical University

    Smolensk, Russia

  • Bashkir State Medical University/Department of Outpatient and Emergency Pediatrics

    Ufa, Russia

  • Volgograd State Medical University/Department of Pediatrics and Neonatology

    Volgograd, Russia

  • Yaroslavl State Medical University/Department of Pediatrics IPGE

    Yaroslavl, Russia

  • Yaroslavl State Medical University/Department of Pediatrics № 2

    Yaroslavl, Russia

  • Clinical Hospital # 2

    Yaroslavl, Russia

  • LLC "European Medical Center "UMMC-Health"

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.